Skip to main content

Gowthami Morey Arepally

Professor of Medicine
Medicine, Hematology
Duke Box 3486, Durham, NC 27710
Rm 356A Sands Bldg, Research Drive, Durham, NC 27710

Research Interests


Our laboratory conducts translational studies of hematologic disease. Using heparin induced thrombocytopenia (HIT) as a model disease, we apply in vitro, ex-vivo and in vivo approaches to uncover disease mechanisms, model disease and apply discoveries to patient care. Beyond HIT, our laboratory is investigating biomarkers of venous thrombosis and HIT, complement's role in other immune-complex disorders and mechanisms of classical pathway regulation.

Selected Grants


Stimulating Access to Research in Residency (StARR) - NHLBI

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2018 - 2028

Mid-Atlantic praGmatic NETwork for Inclusive Clinical trials in emergency care (MAGNETIC)

ResearchCollaborator · Awarded by National Institutes of Health · 2023 - 2028

ALEXION Study ITP Translational Study

ResearchPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2022 - 2027

Characterization of a Novel E. coli Type III Secretion System Associated with Increased Patient Mortality

ResearchAdvisor · Awarded by National Institutes of Health · 2022 - 2027

Stimulating Access to Research in Residency (StARR) - NHLBI

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2018 - 2028

Mid-Atlantic praGmatic NETwork for Inclusive Clinical trials in emergency care (MAGNETIC)

ResearchCollaborator · Awarded by National Institutes of Health · 2023 - 2028

ALEXION Study ITP Translational Study

ResearchPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2022 - 2027

Characterization of a Novel E. coli Type III Secretion System Associated with Increased Patient Mortality

ResearchAdvisor · Awarded by National Institutes of Health · 2022 - 2027

Hematology & Transfusion Medicine (T32)

Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 1975 - 2026

Comparative studies of complement responses to ICs

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2025

MOMENTA MOM-M281-006

Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2022 - 2025

Complement and Thrombosis in HIT

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2024

T-TAS 01 HD Chip

ResearchPrincipal Investigator · Awarded by Hikari Dx, Inc. · 2024 - 2024

Duke CTSA (TL1) Year 5

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2018 - 2024

Unified Program for Therapeutics in Children

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2019 - 2024

Proteomic Determination of Complement Activation in Postoperative Delirium

ResearchAdvisor · Awarded by University of Washington · 2023 - 2024

An Acoustofluidic Device for Biocompatible Platelet Separation

ResearchCo Investigator · Awarded by Ascent Bio-Nano Technologies, Inc. · 2022 - 2024

Novel development ofan acoustofluidic device for targeted antibody removal in pediatric organ transplan rejection

ResearchCollaborator · Awarded by National Institutes of Health · 2021 - 2023

Acoustic Device to Prevent Antibody Mediated Organ Transplant Failure

ResearchCollaborator · Awarded by Hartwell Foundation · 2019 - 2023

Role of Complement Receptors in cellualr activation by HIT immune complexes

ResearchPrincipal Investigator · Awarded by American Society of Hematology · 2021 - 2022

Platelet Kinetics in Acute Thrombus Formation in Healthy and VTE Patients

FellowshipMentor · Awarded by Society for Academic Emergency Medicine · 2019 - 2022

Variability in neutrophil activation

ResearchMentor · Awarded by National Institutes of Health · 2020 - 2022

Complement and CR2/CD21 in the Immune Pathogenesis of HIT(R01)

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2018 - 2022

Defining the role of therapeutic plasma exchange in heparin induced thrombocytopenia

ResearchMentor · Awarded by Hemophilia & Thrombosis Research Society · 2017 - 2020

An Acoustofluidic Device for Biocompatible Platelet Separation

ResearchCo Investigator · Awarded by Ascent Bio-Nano Technologies, Inc. · 2018 - 2020

Biological Significance of Protamine/Heparin Antibodies

ResearchMentor · Awarded by National Institutes of Health · 2015 - 2020

Probing the heparin structural elements for high risk of heparin-induced thrombocytopenia (HIT)

ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2013 - 2019

Duke-UNC Clinical Hematology and Transfusion Research Career Development Program

ResearchMentor · Awarded by National Institutes of Health · 2006 - 2019

Probing the heparin structural elements for high risk of heparin-induced thrombocytopenia (HIT)

ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2016 - 2018

Clinical Study Protocol for External Performance Evaluation of INNOVANCE Heparin on BCS XP┬┐Method Comparison

Clinical TrialPrincipal Investigator · Awarded by Siemens Healthcare Diagnostics · 2016 - 2018

Clinical Study Protocol for External Performance Evaluation of INNOVANCE Heparin on BCS XP, Method Comparison

ResearchPrincipal Investigator · Awarded by Siemens Healthcare Diagnostics · 2017 - 2017

Cellular Basis of HIT Immune Response in Cardiac Surgery

ResearchMentor · Awarded by Children's Hospital of Philadelphia · 2012 - 2017

Biological Significance of Protamine/Heparin Antibodies

ResearchMentor · Awarded by Hemostasis & Thrombosis Research Society · 2015 - 2015

Modeling the spectrum of HIT pathobiology

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2012 - 2014

Biological Significance of Protatmine/Heparin Antibodies

FellowshipPrincipal Investigator · Awarded by National Institutes of Health · 2013 - 2014

Clinical Significance of protamine/heparin antibodies after CPB

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2011 - 2014

Thrombosis and Hemostasis Centers Research and Prevention Network

ResearchConsultant · Awarded by Centers for Disease Control and Prevention · 2002 - 2013

Immune Dysregulation in HIT

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2006 - 2012

Rare Thrombotic Diseases Clinical Research Network

ResearchCo Investigator · Awarded by National Institutes of Health · 2004 - 2010

Pathogenesis of Thrombosis in HIT

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1999 - 2004

External Relationships


  • ABCAM PLC
  • Alexion Pharmaceuticals, Inc. a subsidiary of AstraZeneca
  • Annexon
  • AstraZeneca
  • Biokit
  • ABCAM PLC
  • Alexion Pharmaceuticals, Inc. a subsidiary of AstraZeneca
  • Annexon
  • AstraZeneca
  • Biokit
  • Janssen Research & Development
  • Sanofi
  • Veralox therapeutics

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.